Last reviewed · How we verify
Hypo-osmolar ORS
At a glance
| Generic name | Hypo-osmolar ORS |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Introduction of Hypo-osmolar ORS for Routine Use (PHASE4)
- New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management- Surveillance Study for Adverse Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypo-osmolar ORS CI brief — competitive landscape report
- Hypo-osmolar ORS updates RSS · CI watch RSS
- International Centre for Diarrhoeal Disease Research, Bangladesh portfolio CI